News

Obesity Drugs' CV Risk Assessment Needs Hard End Points


 

FROM A MEETING OF THE FDA'S ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE

"That makes perfect sense to me. I’ll go along with that," said Dr. Michael A. Proschan of the National Institute of Allergy and Infectious Diseases in Bethesda, Md. That "sounds like a reasonable idea," Erica Brittain, Ph.D., also of NIAID, agreed.

Cathy Dombrowski is with "The Pink Sheet." Both this news organization and "The Pink Sheet" are owned by Elsevier.

Pages

Recommended Reading

FDA Says Weight Loss Drug Needs CV Outcome Trial
MDedge Cardiology
Her Chief Complaint Is ... And by the Way She’s Also Pregnant
MDedge Cardiology
FDA Panel Endorses Obesity Drug Qnexa After All
MDedge Cardiology
Memory Changes, Hyperglycemia Prompt Statin Label Changes
MDedge Cardiology
Duodenal Switch May Excel at Type 2 Diabetes Resolution
MDedge Cardiology
Slight Hyperglycemia Risk Shouldn't Deter Statin Use
MDedge Cardiology
Arthritis Plus Hypothyroidism Ups Women's CVD Risk
MDedge Cardiology
Bariatric Surgery Bests Medication In Obese Diabetics
MDedge Cardiology
Gout Prevalence Has Spiked
MDedge Cardiology
Novel Agent Lowered LDL Up to 72%
MDedge Cardiology